A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT ID: NCT06679985
Last Updated: 2026-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
72 participants
INTERVENTIONAL
2024-12-20
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)
NCT04605796
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
NCT04472767
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
NCT06584071
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
NCT05886257
An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma
NCT05448183
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: Casdozokitug Lower Dose + Toripalimab + Bevacizumab
Casdozokitug
Solution for infusion
Toripalimab
Solution for infusion
Bevacizumab
Solution for infusion
Arm B: Casdozokitug Higher dose + Toripalimab + Bevacizumab
Casdozokitug
Solution for infusion
Toripalimab
Solution for infusion
Bevacizumab
Solution for infusion
Arm C: Toripalimab + Bevacizumab
Toripalimab
Solution for infusion
Bevacizumab
Solution for infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Casdozokitug
Solution for infusion
Toripalimab
Solution for infusion
Bevacizumab
Solution for infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease that is not amenable to curative surgical and/or locoregional therapies or progressive disease (PD) after surgical and/or locoregional therapies.
* ≥ 1 measurable lesion (per RECIST v1.1) that is untreated.
Exclusion Criteria
* Has previously received an anti-IL-27 antibody (Ab) or anti-IL-27-targeted therapy.
* Has known fibrolamellar HCC histology, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
* Has moderate or severe ascites.
* Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Coherus Oncology, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Winship Cancer Institute Emory University
Atlanta, Georgia, United States
Mayo Clinic - Scottsdale
Scottsdale, Arizona, United States
University of Arizona - Cancer Center
Tucson, Arizona, United States
Beverly Hills Cancer Center
Beverly Hills, California, United States
City of Hope
Duarte, California, United States
City of Hope at Irvine Lennar
Irvine, California, United States
Cancer & Blood Specialty Clinic
Lakewood, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Sarcoma Oncology Center
Santa Monica, California, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
Mountain States Tumor Institute at St. Luke's Regional Medical Center
Boise, Idaho, United States
University of Kansas Cancer Center
Kansas City, Kansas, United States
UofL Health Brown Cancer Center
Louisville, Kentucky, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
Christus St. Vincent Regional Medical Center
Santa Fe, New Mexico, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
University of North Carolina (UNC) - Chapel Hill
Chapel Hill, North Carolina, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)
Columbus, Ohio, United States
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Prisma Health Cancer Institute
Greenville, South Carolina, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
UW Carbone Cancer Center - Cancer Connect
Madison, Wisconsin, United States
Royal Brisbane and Women's Hospital
Herston, Brisbane, Australia
Bankstown-Lidcombe Hospital
Bankstown, New South Wales, Australia
Monash Health
Melbourne, Victoria, Australia
St Vincent's Hospital Sydney
Darlinghurst, , Australia
Linear Clinical Research
Nedlands, , Australia
Sunnybrook Health Sciences Centre - Bayview Campus
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Prince of Wales Hospital
Shatin, New Territories, Hong Kong
Queen Mary Hospital
Hong Kong, Pok Fu Lam, Hong Kong
Humanity & Health Clinical Trial Centre
Hong Kong, , Hong Kong
National Cancer Centre Singapore
Singapore, , Singapore
Tan Tock Seng Hospital
Singapore, , Singapore
Curie Oncology
Singapore, , Singapore
China Medical University Hospital
Taichung, Taichung City, Taiwan
National Cheng Kung University Hospital
Tainan, Tainan City, Taiwan
National Taiwan University Hospital
Tainan, Taipei City, Taiwan
Taipei Veterans General Hospital
Taipei, Taipei City, Taiwan
Chi Mei Medical Center
Tainan, , Taiwan
Linkou Chang Gung Memorial Hospital (CGMHLK)
Taoyuan, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
Role: primary
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHS-388-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.